Mick J M van Eijs

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 14

Top Topics

Systematic Review

Juvenile Idiopathic Arthritis

Peripheral Blood

Top Venues

Cancer immunology, immunotherapy : CII

NPJ precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Laura M Timmerman, Lobke C M Hensen, Mick J M van Eijs, Rik J Verheijden, Karlijn P M Suijkerbuijk, Linde Meyaard, Michiel M van der Vlist, null null
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Laura M Timmerman, Lobke C M Hensen, Mick J M van Eijs, Rik J Verheijden, Karlijn P M Suijkerbuijk, Linde Meyaard, Michiel M van der Vlist, null null
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Laura M Timmerman, Lobke C M Hensen, Mick J M van Eijs, Rik J Verheijden, Karlijn P M Suijkerbuijk, Linde Meyaard, Michiel M van der Vlist, null null
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Laura M Timmerman, Lobke C M Hensen, Mick J M van Eijs, Rik J Verheijden, Karlijn P M Suijkerbuijk, Linde Meyaard, Michiel M van der Vlist, null null
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Laura M Timmerman, Lobke C M Hensen, Mick J M van Eijs, Rik J Verheijden, Karlijn P M Suijkerbuijk, Linde Meyaard, Michiel M van der Vlist, null null
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Karlijn P M Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, Alexander M M Eggermont
Clinical and translational attributes of immune-related adverse events. Nature cancer (2024)
Karlijn P M Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, Alexander M M Eggermont
Clinical and translational attributes of immune-related adverse events. Nature cancer 5 (4) (2024)
Laura M Timmerman, Lobke C M Hensen, Mick J M van Eijs, Rik J Verheijden, Karlijn P M Suijkerbuijk, Linde Meyaard, Michiel M van der Vlist, null null
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Karlijn P M Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, Alexander M M Eggermont
Clinical and translational attributes of immune-related adverse events. Nature cancer 5 (4) (2024)
Karlijn P M Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, Alexander M M Eggermont
Clinical and translational attributes of immune-related adverse events. Nature cancer 5 (4) (2024)
Rik J Verheijden, Mick J M van Eijs, Anne M May, Femke Van Wijk, Karlijn P M Suijkerbuijk
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ precision oncology 7 (1) (2023)
Mick J M van Eijs, Rik J Verheijden, Stefanie A van der Wees, Stefan Nierkens, Anne S R van Lindert, Karlijn P M Suijkerbuijk, Femke Van Wijk, null null
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition. Cancer immunology, immunotherapy : CII (2023)
Rik J Verheijden, Mick J M van Eijs, Anne M May, Femke Van Wijk, Karlijn P M Suijkerbuijk
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ precision oncology 7 (1) (2023)
Mick J M van Eijs, Lotte E van der Wagen, Rogier Mous, Roos J Leguit, Lisette van de Corput, Anne S R van Lindert, Britt B M Suelmann, Anna M Kamphuis, Stefan Nierkens, Karlijn P M Suijkerbuijk
Hematologic malignancies following immune checkpoint inhibition for solid tumors. Cancer immunology, immunotherapy : CII (2022)